Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
Takeda
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Acerta Pharma BV
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Novartis
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
Pharmacyclics LLC.
M.D. Anderson Cancer Center
GlaxoSmithKline
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Amgen
M.D. Anderson Cancer Center
City of Hope Medical Center
Arog Pharmaceuticals, Inc.
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
University of Nebraska
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Albert Einstein College of Medicine
Northwell Health
Bristol-Myers Squibb
Alliance for Clinical Trials in Oncology